FDA intends to have an Advisory Committee meeting for Multaq® (dronedarone) on March 18, 2009

Paris, France, – November 27, 2008 – Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has informed the company that they intend to discuss the dronedarone application at the Cardio-Renal Advisory Committee on March 18, 2009.

Dronedarone was granted by the FDA a priority review status on July 31, 2008.

About dronedarone (Multaq®)

Dronedarone (Multaq®) is an investigational treatment and the only Anti-Arrhythmic Drug (AAD) to have shown a significant reduction in morbidity and mortality in AF/AFL patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity. Dronedarone, discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 6,200 patients. The landmark ATHENA trial is the only double-blind, anti-arrhythmic, morbidity-mortality study in patients with AF and enrolled a total of 4,628 patients.

Dronedarone is one of the major therapeutic innovations in atrial fibrillation for the last twenty years.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, contributes to improving life by providing a broad offering of medicines, vaccines, and integrated healthcare solutions adapted to local needs and means. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Sanofi-aventis : www.sanofi-aventis.com
Media Relations : Tél. : (+) 33 1 53 77 44 50 - e-mail **:** MR@sanofi-aventis.com
Investor Relations : Tél. : (+) 33 1 53 77 45 45 - e-mail **:** IR@sanofi-aventis.com